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women and 42% non-smokers), recruited at two French centers participating in the
European Community Respiratory Health Survey. Lung function was expressed as a
percentage of predicted FEV1. CRP was measured centrally, by means of a highly
sensitive assay.
In cross-sectional analysis, FEV1 as a % of predicted values was negatively
associated with serum CRP concentration (P ¼ 0:002). Multivariate adjustment did
not alter these results (P ¼ 0:002). In longitudinal analysis, annual FEV1 decline
tended to increase from the lower to the upper tertile for baseline CRP
concentration but the association was borderline significant (P ¼ 0:14). Mean values
of annual FEV1 decline were 26732, 31732, and 34732ml/year for the lower,
middle and upper tertiles of baseline CRP concentration, respectively, after
adjusting for potential confounders (P ¼ 0:09). Changes in CRP levels during
follow-up were associated with annual FEV1 decline. The mean annual FEV1 declines
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CRP and lung function 2113CRP were 36731, 30731 and 24731ml/year, respectively (Po0:001). These
findings were not affected by adjustment for potential confounders (P ¼ 0:002).
In conclusion, increases in CRP levels over time were associated with a steeper
FEV1 decline.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Reduced pulmonary function, as assessed by peak
expiratory flow, forced expiratory volume in 1 s
(FEV1) and forced vital capacity (FVC), is associated
with an increase in the occurrence of vascular
alterations and cardiovascular morbidity and mor-
tality, in both smokers and non-smokers.1–7
Systemic inflammation may play a key role in the
development of cardiovascular risk8–10 and reduced
pulmonary function.11–14 There are various markers
of systemic inflammation. C-reactive protein (CRP),
an acute-phase reactant produced primarily in the
liver in response to interleukin-6, is the best
studied, and its concentration has consistently
been shown to be strongly related to future
cardiovascular risk in healthy subjects and in
patients with peripheral and stable coronary artery
diseases.15–17
Systemic inflammation may also be involved
in lung function decline, as suggested by the results
of the few available cross-sectional population-
based studies. FVC has been reported to be
inversely associated with levels of inflammation-
sensitive serum proteins.18 A lower FEV1 and an
increased risk of chronic obstructive pulmonary
disease (COPD) have also been shown to be
associated with high serum fibrinogen concentra-
tion.12 High serum CRP concentrations have been
reported in patients with COPD, which is a major
cause of reduced FEV1.
19 However, the relation-
ships between serum CRP concentration and lung
function have not been studied in detail. A few
cross-sectional studies, including one carried out by
our group, have investigated the association be-
tween serum CRP concentration and pulmonary
function in the general population.20,21 In these
studies, FEV1 was inversely associated with CRP
concentration.
Cross-sectional studies cannot be used to deter-
mine direction- and time-dependent relationships.
No longitudinal study has investigated the relation-
ship between changes in CRP concentration and
pulmonary function decline over time.
In this 812 year longitudinal study, conducted in
531 subjects aged between 20 and 44 years at
baseline, recruited at two French centers partici-
pating in the European Community RespiratoryHealth Survey (ECRHS), we assessed the associa-
tions between changes in CRP concentration and
annual FEV1 decline.Methods
The ECRHS is an international, longitudinal, multi-
center epidemiological survey of asthma (preva-
lence, determinants, and management) in Europe.
Full details of the original sampling protocol have
been published elsewhere.22,23 In the baseline
study in 1991, 660 subjects (Paris) and 534 subjects
(Grenoble) aged 20–44 years were randomly se-
lected from the electoral rolls of Paris (18th
Arrondissement) and Grenoble. These subjects
were interviewed and examined. Subjects who
had suffered from respiratory infection in the 3
weeks immediately preceding the examination
were asked to postpone their examination if
possible, as this was a criterion for exclusion. Each
subject completed a standardized questionnaire
and underwent standardized lung function and
blood tests.
Between 1999 and 2001 (8.5 years of follow-up
on average), all subjects from the baseline study
were contacted again and asked to undergo
examination again for the follow-up study. In the
two centers, 684 subjects agreed to participate in
the follow-up study. Participants and non-partici-
pants did not differ in sex distribution, body mass
index (BMI) or lung function values. However,
participants were slightly older (36.677.1 vs.
34.977.2 years, Po0:001) and more likely to be
non-smokers (41.8% vs. 35.8%, Po0:001) (Table 1).
The protocol was approved by the French Ethics
Committee for Human Research and by the National
Committee for Data Processing and Freedom.
Informed written consent was obtained from all
the subjects.Data collection
At baseline and follow-up, trained interviewers
used a standardized questionnaire to collect socio-
demographic information and data concerning
respiratory symptoms during the preceding 12
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Table 1 Comparison of baseline characteristics among subjects participating and not participating in the
follow-up study.
Baseline data Participants (n ¼ 684) Non-participants (n ¼ 510) Py
Age (year)z 36.677.1 34.977.2 o0.001
Men (%) 47.7 52.3 0.12
BMI (kg/m2)z 22.673.1 22.773.2 0.66
Smoking habits (%) o0.001
Never smokers 41.8 35.8
Past smokers 25.0 24.2
Light smokers 21.9 19.3
Heavy smokers 11.3 20.8
Atopy (%) 28.4 30.4 0.48
Asthma (%) 6.4 4.7 0.20
FEV1% predicted
y 104.9713.4 104.1713.3 0.27
Subjects completed a questionnaire and underwent spirometry at follow-up study.
yFor differences between the sexes, using Student’s t-test for continuous variables and w2-tests for categorical variables.
zMean7standard deviation.
yFEV1% predicted ¼ (observed FEV1/predicted FEV1) 100.
R. Shaaban et al.2114months, smoking history, allergic symptoms, family
history, home and work environment, and use of
health-care services and medication. Subjects were
classified as never having smoked, past smokers
(those who had stopped smoking at least 1 year
before the examination), heavy smokers (if their
current tobacco consumption was at least 20 g per
day) and light smokers (for those consuming up to
20 g of tobacco per day). Baseline ‘‘asthma’’ was
defined as a positive response to any of the
following questions: ‘‘Have you had an asthma
attack in the last 12 months?’’ and/or ‘‘Are you
currently taking any medication for asthma?’’. BMI
was calculated as weight in kilograms divided by
the square of height in meters.
Lung function measurements
FEV1 was measured with a water-sealed bell
spirometer (Biomedin srl, Padova, Italy). The high-
est of five technically acceptable FEV1 readings was
used for analysis. FEV1 was expressed as a
percentage of predicted values (FEV1% predicted)
calculated based on age and height for men and
women, using ECSC reference equations.24
Biological measurements
Blood samples were collected at baseline and during
follow-up studies and frozen at 80 1C. We deter-
mined the levels of IgE specific for house dust mite,
cat, timothy grass and Cladosporium in serum
samples. Tests for specific IgE were considered
positive if values 40.35 kU/l were obtained.‘‘Atopy’’ was defined as at least one positive specific
IgE test. Total cholesterol, high-density lipoprotein
(HDL) and low-density lipoprotein (LDL) concentra-
tions were determined by enzymatic methods,
using an automatic analyzer. Serum CRP concentra-
tions were determined from frozen blood samples
stored in the Biochemistry Department of Bichat
Hospital, Paris, by means of an ultra-sensitive
competitive immunoassay on a BN II analyzer (Dade
Behring, Marburg, Germany). The intra- and inter-
assay coefficients of variation were both o10%.
Statistical analysis
Statistical analysis was carried out with SAS version
8.2 (SAS Institute Inc., Cary, NC, USA). Data are
expressed as percentages for discrete variables and as
means7standard deviations for continuous variables.
We considered P-values o0.05 to be significant.
We carried out a cross-sectional analysis on data
collected in 1991 (baseline). CRP concentrations
were not normally distributed and analyzes were
therefore performed with log-transformed values
divided into tertiles (the tertile cut-off points for
CRP concentration were 0.5 and 1.3mg/l). We
investigated the cross-sectional association be-
tween CRP and FEV1% predicted by analysis of
variance for univariate analyzes and analysis of
covariance for multivariate analyzes (with FEV1%
predicted as the dependent variable). Cross-sec-
tional multivariate analyzes were adjusted for sex,
center, age, BMI, total cholesterol concentration,
smoking habits (never, past, light, and heavy
smokers), atopy and asthma.
ARTICLE IN PRESS
CRP and lung function 2115For the longitudinal analysis, annual FEV1 decline
(ml/year) was calculated as the difference be-
tween follow-up and baseline observed FEV1 va-
lues, divided by the number of months between the
two surveys, multiplied by 12. The change in serum
CRP concentration during follow-up was calculated
by subtracting CRP concentration at follow-up from
baseline CRP concentration. Subjects were divided
into tertiles according to mean change in CRP
concentration (tertile cut-off points for change in
CRP concentration were 0.1 and 0.5mg/l and
mean7SD for each tertile of CRP change were
1.872.8, 0.170.1, and 3.074.4mg/l, respec-
tively). In the first tertile—‘‘decrease’’—CRP con-
centrations decreased over time. In the second
tertile—‘‘no change’’—CRP concentrations re-
mained stable and in the third tertile—‘‘increa-
se’’—CRP concentrations increased over time.
Categories of change in smoking habits were
derived, which included never smokers, sustained
quitters, smokers (at each survey), quitters
(stopped between surveys), and restarters.
We used analysis of variance and analysis of
covariance to describe the differences in mean
annual FEV1 decline between the tertiles of both
baseline CRP and change in CRP concentration,
with and without adjustment for center, sex, and
baseline age, BMI, total cholesterol concentration,
smoking habits, atopy, asthma and FEV1. In addi-
tion, changes in these confounding factors during
follow-up were included in the multivariable model
to assess its potential effects on this relationship.
We excluded 153 of the 684 subjects from the
analysis, for the following reasons: missing data for
serum CRP concentration (n ¼ 144, due to the
refusal of the subject to provide blood samples or
technical and organizational difficulties) and/or
missing pulmonary function tests (n ¼ 14). This left
531 subjects for whom complete data were avail-
able for cross-sectional and longitudinal analysis.
The 531 subjects with complete data were older at
baseline (37.077.0 vs. 35.677.1 years, P ¼ 0:03)
than the excluded subjects and the percentage of
men was higher (50.0% vs. 39.0%, P ¼ 0:01). The
mean duration of follow-up was 8.570.8 years.
Men had a higher mean baseline FEV1% predicted
than women but serum CRP concentrations were
similar in men and women.Results
Mean baseline age (7SD) for the 531 subjects (50%
men) included in this study was 37.077.0 years.
About 42% of this population was non-smoker . Asexpected, mean BMI and mean total cholesterol
concentrations were significantly higher in men
than in women. Women had higher serum concen-
trations of HDL than men. Heavy smokers were
more frequent in men than in women (results
not shown). Men had a higher mean baseline
FEV1% predicted than women (107714 vs.
104713, Po0:01) but serum CRP concentrations
were similar in men and women (1.5772.5 vs.
1.6072.5, P ¼ 0:86). Baseline characteristics were
compared by tertiles of baseline CRP. CRP was
positively associated with BMI (Po0:001), smoking
status (Po0:01), total cholesterol (Po0:001) and
asthma (P ¼ 0:05) (results available from authors).Cross-sectional analysis
At baseline, FEV1% predicted was negatively asso-
ciated with serum CRP concentration. Crude mean
values of FEV1% predicted according to CRP tertiles
were 106714%, 107713%, and 102714% for lower,
middle and upper tertiles, respectively (P ¼ 0:002).
Similar results were obtained in multivariate
analyzes: the participants with the highest serum
CRP concentrations had the lowest values of FEV1%
predicted (Table 2). This pattern applied to the
various subgroups. The associations between CRP
concentration and FEV1% predicted were weaker
(and not significant) in those who had never
smoked. However, the interaction between CRP
concentration and smoking habits was not statisti-
cally significant (P ¼ 0:5).Longitudinal study
A significant correlation was observed between
baseline CRP and CRP at follow-up (correlation
coefficient ¼ 0.50, Po0:001) and also between
baseline FEV1%predicted and FEV1%predicted at
follow-up (correlation coefficient ¼ 0.83, Po0:001).
Mean annual decline in FEV1 (7SD) was
30732ml/year (Po0:001). CRP concentration in-
creased over time and the mean change in CRP
concentration over the eight and a half years of
follow-up was 0.573.6mg/l (P ¼ 0:004). Baseline
BMI, smoking and asthma were positively asso-
ciated with change in CRP concentration over time.
Baseline FEV1 was not associated with CRP change
(Table 3). Annual FEV1 decline was positively
associated with being female, age, smoking,
and BMI at baseline (results available from the
authors).
Table 4 shows the relationship between baseline
CRP and FEV1 decline. Annual FEV1 decline tended
to increase from the lower to the upper tertile for
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Table 2 Cross-sectional analysis: multivariate relationships between CRP concentration and FEV1% predicted;
in all subjects and in subgroups.
FEV1% predicted Baseline CRP by tertiles
y P for
association
P for trend
I II III
Lower
(N ¼ 179)
Middle
(N ¼ 183)
Upper
(N ¼ 169)
All (n ¼ 531) 107714 107713 102714 0.002 0.006
Men (n ¼ 267) 108715 108714 104714 o0.01 0.052
Women (n ¼ 264) 105713 106713 100715 o0.05 0.075
Never smokers (n ¼ 224) 107713 108713 105715 0.59 0.65
Current and past smokers
(n ¼ 307)
107713 106713 101713 0.002 0.002
Non-asthmatics (n ¼ 496) 108713 107713 103715 0.005 0.002
Models adjusted (where applicable) for center, age, sex, smoking habits, body mass index, cholesterol levels, atopy, and
asthma.
yCut-off points of tertiles: 0.5 and 1.3mg/l.
Table 3 Relationship between change in CRP concentration and baseline factors.
Baseline variable CRP change by tertiles P
I II III
Decrease (N ¼ 178) No change (N ¼ 176) Increase (N ¼ 177)
Paris (%) 53.4 48.3 40.7 0.05
Age (year)y 37.077.1 36.977.1 37.177.1 0.99
Sex: men (%) 45.5 51.7 53.7 0.28
BMI (kg/m2)y 22.773.4 22.472.4 23.273.4 0.02
Total cholesterol (g/l)y 2.1770.5 2.1170.4 2.1470.5 0.50
HDL cholesterol (g/l)y 0.5570.15 0.5670.16 0.5370.14 0.14
LDL cholesterol (g/l)y 1.3770.45 1.3170.36 1.3370.41 0.42
Smoking habits (%) o0.001
Never smokers 38.8 54.0 33.9
Past smokers 22.5 25.6 27.7
Light smokers 26.4 15.9 19.8
Heavy smokers 12.4 4.6 18.6
Asthma (%) 4.1 4.0 10.7 0.02
Atopy (%) 26.0 26.9 32.8 0.31
FEV1% predicted
z 107714 107714 105714 0.34
Cut-off points of CRP concentration change: 0.1 and 0.5mg/l.
yMean7SD.
zFEV1% predicted ¼ (observed FEV1/predicted FEV1) 100.
R. Shaaban et al.2116baseline CRP concentration but this relationship did
not reach statistical significance. After adjustment
for covariates including, center, sex, baseline age,
smoking habits, BMI, asthma, atopy, FEV1 and
change in CRP concentration, the association
between baseline CRP and annual FEV1 decline
concentration was borderline significant (P ¼ 0:09),
but a significant difference in mean FEV1 decline
was seen between the highest and lowest tertiles
for baseline CRP (P ¼ 0:03).Changes in CRP concentration during follow-up
were negatively correlated with FEV1 decline
(correlation coefficient ¼ 0.15, Po0:001—
Fig. 1). Mean annual FEV1 decline was highest
(36731ml/year) for the upper tertile (increase in
CRP concentration over time), lowest (24731ml/
year) for the lower tertile (decrease in CRP
concentration over time), and intermediate
(30731ml/year) in the second tertile (Po0:001).
Similar results were obtained after adjustment for
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Table 4 Longitudinal analyses: relationships between baseline C-reactive and annual decline in FEV1.
FEV1 decline
(ml/year)
Baseline CRP by tertiles P for association P for trend
I II III
Unadjusted 25731 31730 32731 0.14 0.07
Adjustedy 26732 31732 34732 0.09 0.02
Cut-off points of tertiles: 0.5 and 1.3mg/l.
yModels adjusted for center, sex, baseline age, smoking habits, body mass index, cholesterol levels, atopy, asthma, FEV1 and
change in CRP concentration.
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Figure 1 Relationship between CRP change during
follow-up and annual FEV1 decline (correlation
coefficient ¼ 0.15; Po0:001).
CRP and lung function 2117baseline factors (P ¼ 0:002): the greater the
increase in CRP concentration, the steeper the
decline of FEV1. Subjects in the upper tertile for
changes in CRP concentration displayed a greater
annual FEV1 decline than subjects in the lower
tertile (13ml greater for men and 11ml greater for
women), whereas the annual decline in FEV1 is
around 30ml/year in adults.23 Adding changes over
time in confounding factors (smoking habits,
asthma, atopy, BMI, and lipid concentrations) to
the multivariate model did not alter these findings
(Table 5). Similar results were obtained if analyzes
were carried out after excluding asthmatics,
separately in men and in women, and according
to baseline smoking habits (Table 5).Discussion
In this population-based study, conducted in young
and middle-aged subjects, FEV1 and serum CRP
concentration were negatively related both in
cross-sectional and in longitudinal analyzes. These
associations were independent of potential con-founding factors (particularly smoking habits) and
were observed in subgroups defined on the basis of
sex, smoking habits and asthma status. This is the
first longitudinal study to investigate the relation-
ship between serum CRP concentration and lung
function decline. Cross-sectional relationships be-
tween inflammation and lung function has been
demonstrated previously in even larger population
samples.18,20 Some studies have shown that severe
(FEV1o 50% of predicted) and moderate (FEV1
50–80% of predicted) COPD is associated with low-
grade systemic inflammation.24,25 Our study con-
firms and extends previous findings by demonstrat-
ing the presence of systemic inflammation even in
subjects with modest decreases in pulmonary
function. These associations seem to be relatively
strong and may be considered clinically relevant.
Subjects in the upper tertile for change in CRP
concentration had an excess annual FEV1 decline of
13ml for men and 11ml for women over subjects in
the lower tertile.
Baseline CRP levels also tended to be related to
annual FEV1 decline. However, the association was
of borderline statistical significance. This may
reflect the low levels of variability in CRP responses
in healthy young and middle-aged subjects. More-
over, analyzes based on a single baseline measure-
ment and the within-person variability of CRP will
tend to underestimate the effect of CRP on
subsequent pulmonary function decline (regression
dilution bias).26
The strengths of this study include the use of
data from a general population sample with high-
quality, standardized measurements, as part of the
ECRHS.27,28 We were able to confirm previously
reported associations between annual FEV1 decline
and major risk factors, including baseline age,
smoking habits and BMI, and the associations of CRP
with BMI and with smoking habits observed are
consistent with previously published results.28–30
Although the rate of participation in this study
(around 60%) is acceptable for such a long follow-up
study in the general population (mean of 8.5
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Table 5 Longitudinal multivariate analyses: relationships between change in C-reactive protein concentration
during follow-up and decline in FEV1.
FEV1 decline (ml/year) CRP change by tertiles
 P for
association
P for trend
I II III
Decrease No change Increase
Unadjusted 24731 30731 36731 0.009 0.002
Adjusted for confounding factorsy at
baseline
21730 26730 32730 o0.01 0.002
Men 23733 28733 36733 0.08 0.15
Women 20726 25726 31726 0.02 0.01
Never smokers 24728 32728 38728 0.02 0.01
Current and past smokers 25732 28732 36732 0.04 0.02
Non asthmatics 25729 30729 39729 0.001 0.001
Adjusted for confounding factorsy at
baseline and follow-up
26732 30731 35732 0.04 0.01
Cut-off points of CRP concentration change: 0.1 and 0.5mg/l.
yModels adjusted (as appropriate) for center, sex, age, smoking habits, body mass index, cholesterol levels, atopy, asthma,
and baseline FEV1 and CRP.
R. Shaaban et al.2118years), we cannot rule out the possibility that there
was a selection bias. Nevertheless, our population
consisted mostly of young and middle-aged adults,
so a significant proportion of the subjects lost to
follow-up probably simply moved out of the area.
Furthermore, our comparisons of participating and
excluded subjects identified no differences in
pulmonary parameters and CRP concentrations
between these two groups.
We also analyzed the extent to which these
associations were accounted for by confounding
factors, such as smoking. It is now widely accepted
that smoking is the main risk factor for reduced
pulmonary function and COPD.31 Compounds pre-
sent in tobacco smoke also penetrate into the
bloodstream, and are associated with a higher
prevalence of coronary artery disease, endothelial
dysfunction, and high serum concentrations of
markers of systemic inflammation.32–34 High CRP
concentrations may reflect the effects of smoking,
but adjustment for smoking habits had no effect on
the observed association, and the observation that
changes in CRP concentration were associated with
FEV1 decline in those who had never smoked
renders it unlikely that this association is due to
smoking.
Unknown or, to a lesser extent, unmeasured
underlying conditions generating both high serum
CRP concentrations and impaired pulmonary func-
tion via other mechanisms, may also result in
confounding effects. The exclusion of subjects with
CRP concentrations 410mg/l (n ¼ 9) had little or
no effect on the reported associations.The reasons for the inverse association between
systemic inflammation and reduced pulmonary
function are unclear but several mechanisms may
be involved. Firstly, reduced lung function may be
responsible for the observed systemic inflamma-
tion. Like hepatocytes, inflammatory lung or
pulmonary epithelial cells, have been shown to
express CRP and IL-6.35,36 COPD, a leading cause of
reduced FEV1, is characterized by major lung
inflammation.37 This condition is associated with
high serum concentrations of CRP and IL-6.24,38 The
production of IL-6 in the airways also increases in
COPD.41 IL-6 may reach the bloodstream, stimulat-
ing the production of CRP and other inflammatory
mediators by the liver, sequentially activating
pulmonary inflammatory cells during transit
through the pulmonary circulation.39 It was re-
cently shown that inhaled corticosteroids may
down-regulate IL-6 production in the airways,
leading to a decrease in liver CRP production in
patients with COPD.40 An alternative mechanism—
reverse causation—cannot be excluded. High levels
of cytokines and acute-phase reactants in the
peripheral circulation may be a cause rather than
a consequence of poor lung function. There is
increasing evidence that cytokines—especially
IL-6, which is the chief stimulator of CRP produc-
tion—play a major role linked to the activation and
adhesion of inflammatory cells to the pulmonary
capillary endothelium, leading to changes in
endothelial function and increases in pulmonary
vascular filtration.41–43 The persistence of systemic
inflammation, and pulmonary micro-filtration, may
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CRP and lung function 2119result in damage to the airways, accelerating the
age-related decline in FEV1 and leading to COPD.Conclusion
The results of this population-based study suggest,
for the first time, that increases in serum CRP
concentration over time are associated with a
significant decline of pulmonary function, consis-
tent with the hypothesis that low-grade systemic
inflammation is associated with pulmonary impair-
ment. However, the nature of these relationships is
unclear and merits additional investigation.
Further investigations are also needed to deter-
mine whether lowering serum CRP concentration
could in itself slow FEV1 decline.Acknowledgments
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